Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales’ disease

PURPOSE: This study aimed to report the use of intravitreal bevacizumab as an adjunctive treatment in two cases of advanced Eales’ disease with vitreous haemorrhage and tractional retinal detachment, prior to vitreoretinal surgery. METHOD: In two patients presenting with vitreous haemorrhage, retina...

Descripción completa

Detalles Bibliográficos
Autores principales: Thakar, Meenakshi, Bamrolia, Naina R., Raina, Usha Kaul, Ghosh, Basudeb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345052/
https://www.ncbi.nlm.nih.gov/pubmed/22089976
http://dx.doi.org/10.1007/s12348-011-0049-3
Descripción
Sumario:PURPOSE: This study aimed to report the use of intravitreal bevacizumab as an adjunctive treatment in two cases of advanced Eales’ disease with vitreous haemorrhage and tractional retinal detachment, prior to vitreoretinal surgery. METHOD: In two patients presenting with vitreous haemorrhage, retinal neovascularisation and localised tractional retinal detachment, 1.25 mg of intravitreal bevacizumab was injected prior to vitrectomy, membrane peeling and endolaser photocoagulation of retina. RESULT: Regression of the retinal neovascularisation with resolution of dye leakage on fluoroscein angiography was observed in both cases. Membrane peeling could be performed with minimal bleeding during vitreoretinal surgery in both cases. CONCLUSION: Bevacizumab may be a possible adjunctive treatment to vitreoretinal surgery for the management of Eales’ disease with tractional retinal detachment.

Ejemplares similares